| scholarly article | Q13442814 |
| P50 | author | Steven Zimmerman | Q7615410 |
| Kali A Miller | Q86641508 | ||
| P2093 | author name string | Lien Nguyen | |
| Yuan Fu | |||
| Anne M Baranger | |||
| Long M Luu | |||
| Amin Haghighat Jahromi | |||
| P2860 | cites work | Investigating the binding mode of an inhibitor of the MBNL1·RNA complex in myotonic dystrophy type 1 (DM1) leads to the unexpected discovery of a DNA-selective binder | Q36546738 |
| RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy | Q36673701 | ||
| Polyacrylamides bearing pendant alpha-sialoside groups strongly inhibit agglutination of erythrocytes by influenza A virus: multivalency and steric stabilization of particulate biological systems | Q36724102 | ||
| Threading polyintercalators with extremely slow dissociation rates and extended DNA binding sites | Q37262745 | ||
| Mechanisms of RNA-mediated disease. | Q37310643 | ||
| A simple ligand that selectively targets CUG trinucleotide repeats and inhibits MBNL protein binding. | Q37364023 | ||
| Pentamidine reverses the splicing defects associated with myotonic dystrophy. | Q37413602 | ||
| Chemical reversal of the RNA gain of function in myotonic dystrophy | Q37413606 | ||
| Pathogenic mechanisms of myotonic dystrophy | Q37414636 | ||
| MBNL1-RNA recognition: contributions of MBNL1 sequence and RNA conformation | Q37473486 | ||
| Molecular therapy in myotonic dystrophy: focus on RNA gain-of-function | Q37734660 | ||
| RNA-binding proteins in microsatellite expansion disorders: mediators of RNA toxicity | Q37992334 | ||
| The RNA-binding protein CUGBP1 regulates stability of tumor necrosis factor mRNA in muscle cells: implications for myotonic dystrophy | Q38290011 | ||
| Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. | Q38352202 | ||
| Bivalent Smac mimetics with a diazabicyclic core as highly potent antagonists of XIAP and cIAP1/2 and novel anticancer agents. | Q39431861 | ||
| Polyfunctional DNA intercalating agents | Q39739660 | ||
| Calculation of binding isotherms for heterogeneous polymers | Q40496763 | ||
| Effect of spermine conjugation on the cytotoxicity and cellular transport of acridine. | Q40693437 | ||
| A novel CUG(exp)·MBNL1 inhibitor with therapeutic potential for myotonic dystrophy type 1. | Q41825220 | ||
| Towards multivalent CD1d ligands: synthesis and biological activity of homodimeric α-galactosyl ceramide analogues | Q41841063 | ||
| A detergent-based assay for the detection of promiscuous inhibitors | Q42007896 | ||
| Development of a bivalent dopamine D₂ receptor agonist | Q42725946 | ||
| Interaction of a macrocyclic bisacridine with DNA. | Q43693776 | ||
| Design, synthesis, and biological properties of new bis(acridine-4-carboxamides) as anticancer agents | Q44635868 | ||
| Design of a sequence-specific DNA bisintercalator | Q46802972 | ||
| Sulforhodamine B colorimetric assay for cytotoxicity screening. | Q51032435 | ||
| Bivalent dopamine D2 receptor ligands: synthesis and binding properties. | Q51767770 | ||
| The influence of rigid or flexible linkage between two ligands on the effective affinity and avidity for reversible interactions with bivalent receptors. | Q51906243 | ||
| Synthesis of linear polyamines with different amine spacings and their ability to form dsDNA/siRNA complexes suitable for transfection. | Q52902091 | ||
| Dimeric aminoglycosides as antibiotics. | Q54509551 | ||
| Influencing Receptor−Ligand Binding Mechanisms with Multivalent Ligand Architecture | Q56656697 | ||
| The bivalent ligand approach leads to highly potent and selective acylguanidine-type histamine H₂ receptor agonists | Q57098450 | ||
| A reversal of misfortune for myotonic dystrophy? | Q79302040 | ||
| Synthesis and evaluation of acridine- and acridone-based anti-herpes agents with topoisomerase activity | Q83815937 | ||
| Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors | Q88519588 | ||
| Structural insights into CUG repeats containing the 'stretched U-U wobble': implications for myotonic dystrophy | Q27655444 | ||
| Preparation of Discrete Oligoethers: Synthesis of Pentabutylene Glycol and Hexapropylene Glycol by Two Complementary Methods | Q28165992 | ||
| On the nature of the multivalency effect: a thermodynamic model | Q28235850 | ||
| Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy | Q28257074 | ||
| A muscleblind knockout model for myotonic dystrophy | Q28592365 | ||
| Therapeutics development in myotonic dystrophy type 1. | Q30425796 | ||
| New function for the RNA helicase p68/DDX5 as a modifier of MBNL1 activity on expanded CUG repeats | Q30427374 | ||
| CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1. | Q30496276 | ||
| Single-molecule study of the CUG repeat-MBNL1 interaction and its inhibition by small molecules. | Q30541488 | ||
| Bis-acridines as lead antiparasitic agents: structure-activity analysis of a discrete compound library in vitro | Q33279371 | ||
| Rational and modular design of potent ligands targeting the RNA that causes myotonic dystrophy 2. | Q33427148 | ||
| Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3. | Q33474085 | ||
| Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor. | Q33693780 | ||
| In vivo discovery of a peptide that prevents CUG-RNA hairpin formation and reverses RNA toxicity in myotonic dystrophy models | Q33951409 | ||
| Bivalent diketopiperazine-based tropomysin receptor kinase C (TrkC) antagonists | Q34010191 | ||
| Fluorescence characteristics of 5-carboxytetramethylrhodamine linked covalently to the 5' end of oligonucleotides: multiple conformers of single-stranded and double-stranded dye-DNA complexes | Q34040387 | ||
| The structural basis of myotonic dystrophy from the crystal structure of CUG repeats | Q34133251 | ||
| Design of a bioactive small molecule that targets the myotonic dystrophy type 1 RNA via an RNA motif-ligand database and chemical similarity searching | Q34149072 | ||
| Rationally designed small molecules targeting the RNA that causes myotonic dystrophy type 1 are potently bioactive | Q34158462 | ||
| Design strategies for bivalent ligands targeting GPCRs | Q34180510 | ||
| RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1 | Q34257340 | ||
| Targeting nuclear RNA for in vivo correction of myotonic dystrophy | Q34459257 | ||
| Identification of MBNL1 and MBNL3 domains required for splicing activation and repression | Q34779359 | ||
| Acridine derivatives as chemotherapeutic agents | Q34780011 | ||
| Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy | Q34984541 | ||
| RNA Foci, CUGBP1, and ZNF9 are the primary targets of the mutant CUG and CCUG repeats expanded in myotonic dystrophies type 1 and type 2 | Q35474587 | ||
| Using modularly assembled ligands to bind RNA internal loops separated by different distances | Q36045311 | ||
| From dynamic combinatorial 'hit' to lead: in vitro and in vivo activity of compounds targeting the pathogenic RNAs that cause myotonic dystrophy | Q36107041 | ||
| Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation | Q36154872 | ||
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | myotonic dystrophy | Q1860507 |
| P304 | page(s) | 9471-9481 | |
| P577 | publication date | 2013-11-21 | |
| P1433 | published in | Journal of Medicinal Chemistry | Q900316 |
| P1476 | title | Developing bivalent ligands to target CUG triplet repeats, the causative agent of myotonic dystrophy type 1 | |
| P478 | volume | 56 |
| Q51832854 | A Ligand That Targets CUG Trinucleotide Repeats. |
| Q37358384 | A Potent Inhibitor of Protein Sequestration by Expanded Triplet (CUG) Repeats that Shows Phenotypic Improvements in a Drosophila Model of Myotonic Dystrophy. |
| Q45344868 | A general model for predicting the binding affinity of reversibly and irreversibly dimerized ligands. |
| Q26766064 | A journey in bioinspired supramolecular chemistry: from molecular tweezers to small molecules that target myotonic dystrophy |
| Q99553165 | Design of small molecules targeting RNA structure from sequence |
| Q38287631 | Developmental insights into the pathology of and therapeutic strategies for DM1: Back to the basics |
| Q58548529 | Drugging the RNA World |
| Q36392989 | In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models. |
| Q93039359 | Intrinsically cell-penetrating multivalent and multitargeting ligands for myotonic dystrophy type 1 |
| Q33698593 | Lomofungin and dilomofungin: inhibitors of MBNL1-CUG RNA binding with distinct cellular effects |
| Q34248811 | MBNL proteins and their target RNAs, interaction and splicing regulation. |
| Q26783672 | Modeling ALS and FTD with iPSC-derived neurons |
| Q38855524 | Myotonic dystrophy: approach to therapy |
| Q64934075 | Pharmaceutical Applications of Molecular Tweezers, Clefts and Clips. |
| Q38816065 | RNA FISH for detecting expanded repeats in human diseases |
| Q35868044 | RNA Structures as Mediators of Neurological Diseases and as Drug Targets |
| Q34243144 | RNA-protein interactions in unstable microsatellite diseases. |
| Q37723428 | Reduction of Huntington's Disease RNA Foci by CAG Repeat-Targeting Reagents |
| Q35061734 | Small molecules that target the toxic RNA in myotonic dystrophy type 2. |
| Q26858823 | Structure based approaches for targeting non-coding RNAs with small molecules |
| Q90153443 | Synthesis of Menthol Glycinates and Their Potential as Cooling Agents |
| Q59349013 | Targeting RNA in mammalian systems with small molecules |
| Q33588831 | Targeting toxic RNAs that cause myotonic dystrophy type 1 (DM1) with a bisamidinium inhibitor |
| Q64084474 | The TwistDock workflow for evaluation of bivalent Smac mimetics targeting XIAP |
| Q93074975 | Unveiling the druggable RNA targets and small molecule therapeutics |
Search more.